Prescription medicine
Depemokimab Brand names: Exdensur
Depemokimab (Exdensur) is a prescription medicine. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the depemokimab FDA label on DailyMed (effective June 10, 2026); every depemokimab label on DailyMed.
Highlights of the record
FDA label of June 10, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageEXDENSUR is indicated for the add‑on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older.
Forms and strengths
- 100 mg/ml
Injection (solution).
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 27 through July 30, 2026
What is depemokimab used for?
From the label: indications and usageEXDENSUR is indicated for the add‑on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older. Limitations of Use EXDENSUR is not indicated for the relief of acute bronchospasm or status asthmaticus [see Warnings and Precautions ( 5.2 )]. EXDENSUR is an interleukin‑5 (IL‑5) antagonist, a monoclonal antibody (humanized immunoglobulin G1 [IgG1] kappa) indicated for add‑on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older. ( 1 ) Limitations of Use: Not for relief of acute bronchospasm or status asthmaticus.
Conditions named in the indications of depemokimab's FDA labels, with every medicine labeled for each:
Source: FDA drug label (Exdensur), GlaxoSmithKline LLC, effective June 10, 2026 (SPL set 30332b20-2ac0-42ad-a775-d3ca7f5fe29f), via openFDA; the full label on DailyMed
Is there a generic for depemokimab (Exdensur)?
No generic depemokimab is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do FAERS reports show for depemokimab?
The FDA Adverse Event Reporting System holds 27 reports that list depemokimab among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 0 are coded as a death and 15 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as depemokimab?
3 other medicines are given the same way (subcutaneous) and in the same FDA class as depemokimab or labeled mainly for the same use (asthma), the same class first. Asthma lists all 37 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (subcutaneous) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Benralizumab | Asthma | none listed | n/a | No current entry |
| Mepolizumab | Asthma | none listed | n/a | No current entry |
| Tezepelumab | Asthma | none listed | n/a | No current entry |
Every medicine labeled for the same conditions as depemokimab
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to depemokimab
- 3 medicines for the same use
- Depemokimab side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other